PharmaSEAL

PharmaSEAL is a clinical trial management company specializing in the development of innovative solutions for the biopharmaceutical sector, focusing on improving efficiency and transparency in clinical trials. Founded in 2016, PharmaSEAL operates from Nottingham, UK, offering a unique solution for clinical trial management. The company has engaged in three deals, with its most recent funding round occurring on December 15, 2020, where it raised GBP 664 thousand from Seedrs and individual investors, bringing its total amount raised to GBP 664 thousand and valuation to GBP 1. 78 million.

The CEO and founder, Daljit Cheema, has a history of involvement in the healthcare sector, although specific details about previous ventures are not disclosed. PharmaSEAL specializes in clinical trial management and execution through its flagship product, Engility® CTMS eTMF, a cloud-based adaptive platform. This platform integrates clinical trial management with electronic trial master file (eTMF) functionalities for biopharma, medical device manufacturers, contract research organizations, academic institutions, and nutraceuticals and cosmetics companies. Engility® facilitates oversight of both internal and outsourced clinical trials, enhancing collaboration with suppliers and improving decision-making.

The platform accommodates trials of varying sizes and is primarily marketed in North America and Europe. PharmaSEAL generates revenue through a subscription-based model for its Engility® CTMS eTMF platform, allowing clients to access system features without user-based pricing. Clients engage in service agreements that include setup and ongoing support, potentially involving integration with electronic data capture systems. Revenue is derived from these subscription agreements, along with additional income from consulting partnerships and system integration services, tailored according to client needs.

PharmaSEAL aims to enhance its product offerings and market reach following its most recent funding round on December 15, 2020. The company plans to develop new features for the Engility® platform and target expansion into additional European markets by 2022. The funding raised will support these initiatives, including product development and market outreach efforts, leveraging its valuation of GBP 1. 78 million.